

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT

**LUX-VALVE PLUS SUCCESSFULLY COMPLETES A SERIES OF
FEE-FOR-SERVICE COMPASSIONATE USE TREATMENTS
IN THE ASIA-PACIFIC REGION**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that recently, LuX-Valve Plus, our transjugular tricuspid valve replacement product, has been successfully used in a number of hospitals in the Asia-Pacific region for a series of fee-for-service compassionate use treatments, including several cases with rare and complex anatomical structures. The patients’ clinical performance, cardiac function and quality of life improved significantly after the operation, fully proving the product’s features of wide range of application, high reliability, and simple operation.

The LuX-Valve Plus surgical cases were presented at the 2023 Hong Kong Valves Conference held recently in Hong Kong, and were highly recognized by the authoritative experts attending the conference.

The Company continues to promote the use of LuX-Valve Plus in the Asia-Pacific region for fee-for-service compassionate use treatment, and is accelerating its clinical trials for European CE marking and U.S. Food and Drug Administration registration to accelerate the realization of the Company’s internationalization strategy.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jenscare Scientific Co., Ltd.
Mr. LV Shiwen
Chairman and Executive Director

Hong Kong, October 20, 2023

As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.